Product development

Synaffix is a biotechnology company enabling highly-competitive targeted cancer therapeutics using its site-specific antibody-drug conjugate (ADC) technology platform. The platform consistently delivers more effective and better tolerated ADCs compared to all 3 major clinical-stage technologies.

The business model of Synaffix is technology out-licensing where granted patents provide end-to-end protection of the technology and resulting product candidates thru at least 2035.

We anticipate the first-in-human studies evaluating Synaffix ADC technology to be initiated by our partners in 2018.

Area of work

Oncology, Antibody Drug Conjugates

News from Synaffix

Synaffix Announces Deal with ProfoundBio Worth up to $246 Million Providing Access to Multiple Novel Linker-Payload Technologies

22 Jul 21
READ MORE

2020 highlights Pivot Park Community

04 Jan 21
READ MORE

Synaffix Announces 3rd License Taken by ADC Therapeutics

29 May 19
READ MORE